Compound CVT-E002 attenuates allergen-induced airway inflammation and airway hyperresponsiveness, in vivo

✍ Scribed by Cory Ebeling; Yingqi Wu; Christopher Skappak; John R. Gordon; Ramses Ilarraza; Darryl J. Adamko

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 188 KB
• Volume: 55
• Category: Article
• ISSN: 1613-4125
• DOI: 10.1002/mnfr.201100216

✦ Synopsis

Abstract

Immune modulation has been a sought after means of therapy for atopic diseases. CVT‐E002 is an extract derived from North American Ginseng shown to promote T‐helper‐1‐like responses. We determined what effect CVT‐E002 could have in a mouse model of atopic asthma. We report that oral CVT‐E002 inhibited the development of allergic airway inflammation and airway hyperresponsiveness. This correlated with an increased presence of interferon‐γ in the lung, and also increased regulatory T cells and IL‐10. The ability of CVT‐E002 to induce regulatory T‐cell development was also seen in human in vitro co‐cultures.